Comparing with the lenalidomide group (P = 0.041 at day 12 and P = 0.038 at day 14, Fig. 6a middle panel), co-treatment of PD-L1 and 4-1BB antibody exhibited anti-lymphoma activity on SpCas9-PU.1 group (P = 0.035 at day 12 and P = 0.019 at day 14, Fig. 6a right panel). The gene discussed is SPI1; the disease is lymphoma.